Ascelia Pharma Completes FDA Type A Meeting on Orviglance NDA

MALMÖ, SE / ACCESS Newswire / September 10, 2026 / Ascelia Pharma (STO:ACE) completed the previously scheduled Type A meeting with the U.S. Food and Drug Administration (FDA) on September 9, 2026, regarding the Complete Response Letter (CRL) for the …